EUVIMEDEUVIMED entdecken
Crossref

Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study

Oraianthi Fiste iD, Martina Samiotaki, Efstathios Manios, Chrysanthi Trika, Christine Ivy Liacos, Constantine Dimitrakakis, Meletios Athanasios Dimopoulos, Maria Gavriatopoulou, Flora Zagouri

PROTEOMICS – Clinical Applications · 2025

DOI: 10.1002/prca.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2025. Verfasst von Oraianthi Fiste und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics & Laboratory, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Aminopyridines, Purines, Cardiovascular Diseases. Die Arbeit nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin‐dependent kinase 4/6 inhibitors have transformed hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative metastatic breast cancer (BC) therapeutics. Ribociclib has been associated with survival gain, yet its potential cardiovascular toxicities (CVTs) remain an area of uncertainty. Our single‐center study prospectively recruited adult patients in order to assess treatment‐related CVT incidence and spectrum as well as decipher proteins’ differential expression in affected patients by data‐independent acquisition liquid chromatography‐tandem mass spectrometry (DIA LC‐MS/MS). After a median follow‐up of 27.2 months, five cases of CVT have occurred among the 62 enrolled participants (8.06%; mean age, 67 years). CVTs were in the form of asymptomatic QTc prolongation, transient ischemic attack, deep vein thrombosis, syncope, and pericardial effusion, which developed within 7.56 months. The in‐depth proteomics quantified 144 differentially expressed proteins, of which 109 and 35 were down‐ and up‐regulated, respectively, in these five cases (enrolled participants with CVT) compared to five sex‐ and age‐matched controls (enrolled participants without CVT). Negative regulation of endopeptidase activity, phosphatidylcholine metabolism, and immune response were the most affected signaling pathways in the subsequent functional analysis. Large‐scale external validation of our hypothesis‐generating findings could potentially support individualized cardiovascular prevention in BC patients under ribociclib combinational therapy. Summary Ribociclib has unequivocally revolutionized hormone‐dependent metastatic breast cancer therapeutics. Its potential cardiotoxicity, however, remain inadequately characterized, whereas the underlying pathophysiological mechanisms are poorly understood so far. Our prospective case–control study revealed that despite cardiovascular toxicity was not very common (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesPurinesCardiovascular DiseasesCase-Control StudiesProteomicsBreast NeoplasmsProof of Concept StudyCardiotoxicityProtein Kinase InhibitorsProspective StudiesHumansMaleFemaleAgedBreast Neoplasms, MaleMiddle Aged

Stichwörter der Autor:innen

CDK4/6 inhibitorsbreast cancercardio‐oncologyproteomicsribociclib

Substanzen

ribociclibAminopyridinesPurinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Therapeutics & Laboratory, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
  • Institute For Bioinnovation, Biomedical Sciences Research Center "Alexandrer Fleming", Vari, Greece.
  • First Department of Obstetrics and Gynecology, Alexandra University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Oraianthi Fiste

Zitieren

APA

Fiste, O., Samiotaki, M., Manios, E., Trika, C., Liacos, C. I., Dimitrakakis, C., Dimopoulos, M. A., Gavriatopoulou, M., & Zagouri, F. (2025). Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.70021

Vancouver

Fiste O, Samiotaki M, Manios E, Trika C, Liacos CI, Dimitrakakis C, et al. Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study. PROTEOMICS – Clinical Applications. 2025. doi:10.1002/prca.70021

BibTeX
@article{Fiste2025,
  author = {Fiste, Oraianthi and Samiotaki, Martina and Manios, Efstathios and Trika, Chrysanthi and Liacos, Christine Ivy and Dimitrakakis, Constantine and Dimopoulos, Meletios Athanasios and Gavriatopoulou, Maria and Zagouri, Flora},
  title = {Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2025},
  doi = {10.1002/prca.70021}
}
Kostenlos starten →